Abion Inc.
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid c… Read more
Abion Inc. (203400) - Total Liabilities
Latest total liabilities as of June 2025: ₩31.76 Billion KRW
Based on the latest financial reports, Abion Inc. (203400) has total liabilities worth ₩31.76 Billion KRW as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abion Inc. - Total Liabilities Trend (2016–2024)
This chart illustrates how Abion Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Abion Inc. Competitors by Total Liabilities
The table below lists competitors of Abion Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Polymetals Resources Ltd
AU:POL
|
Australia | AU$78.47 Million |
|
Landec Corporation
F:LDE
|
Germany | €245.74 Million |
|
Lanna Resources Public Company Limited
BK:LANNA
|
Thailand | ฿3.72 Billion |
|
Richmond International Travel & Tours Co Ltd
TWO:2743
|
Taiwan | NT$2.02 Billion |
|
CI Games SA
WAR:CIG
|
Poland | zł111.63 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Abion Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abion Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abion Inc. (2016–2024)
The table below shows the annual total liabilities of Abion Inc. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩35.65 Billion | +2.76% |
| 2023-12-31 | ₩34.69 Billion | +283.65% |
| 2022-12-31 | ₩9.04 Billion | -27.76% |
| 2021-12-31 | ₩12.52 Billion | -62.53% |
| 2020-12-31 | ₩33.41 Billion | +62.93% |
| 2019-12-31 | ₩20.50 Billion | +276.88% |
| 2018-12-31 | ₩5.44 Billion | -0.11% |
| 2017-12-31 | ₩5.45 Billion | -28.23% |
| 2016-12-31 | ₩7.59 Billion | -- |